Liver Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
The liver as a central "hub" of the immune system: pathophysiological implications.
Genetics of liver disease in adults.
Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.
Thyroid hormone action and liver disease, a complex interplay.
Endoplasmic reticulum stress in liver diseases.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
- 1 industry development reported.
Clinical MilestonesViewHide
- 2026-04-01A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)Results expected Q3 2027
- 2025-11-04The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) TrialResults expected Q3 2027
Industry & MarketViewHide
- 2026-06-10A first-in-class pulsatile FXR agonist for bile-acid-related liver diseasesIndustry · Nature News
- 2026-06-10IndustryA first-in-class pulsatile FXR agonist for bile-acid-related liver diseasesIndustry · Nature News
- 2026-04-01ClinicalA Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)Results expected Q3 2027
- 2026-02-28ClinicalNoninvasive Subharmonic Aided Pressure Estimation of Portal HypertensionPrimary completion
- 2025-12-30ClinicalEfficacy and Safety of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With End-stage Liver DiseasesCompleted
- 2025-11-04ClinicalThe Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) TrialResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Jayempi is indicated in combination with other immunosuppressive agents for the prophylax… (2021)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Liver Diseases11
- Liver2
- Betacoronavirus1
- Biological Specimen Banks1
- Cardiovascular Diseases1
- Consensus1
- COVID-191
- Cytokine Release Syndrome1
Leading journals6
- International journal of molecular sciences5
- Hepatology (Baltimore, Md.)4
- Cellular & molecular immunology2
- Gut2
- Cells1
- Diabetes care1
Leading researchers8
- Abadía-Molina F1
- Abecasis GR1
- Adams DH1
- Aggarwal R1
- Ahmadi N1
- Aimo A1
- Ajoolabady A1
- Akbar SMF1
Affiliations (unnormalised)6
- Columbia University2
- Mayo Clinic2
- 2nd Department and Clinic of Paediatrics1
- Aarhus University Hospital1
- Addenbrooke's Hospital1
- Bangabandhu Sheikh Mujib Medical University1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Liver diseases are pathological processes affecting the liver. The literature grounding treats this as an umbrella category that includes acute liver injury, viral hepatitis, alcoholic liver disease, metabolic-associated fatty liver disease, liver fibrosis, and hepatocellular carcinoma.
The supplied grounding indicates that liver diseases can be caused by a variety of pathogenic factors, including viruses, alcohol, and drugs. It also supports an etiologic role for disturbances in the gut microbiota and exposure to dietary and microbial products, but does not define specific disease-by-disease causes beyond these broad categories.
The liver has a complex immunological environment in which metabolic and tissue-remodeling functions involve elements of inflammation. Disease-related mechanisms in the supplied grounding include excessive immune activation, altered macrophage polarization, and interactions with the gastrointestinal microbiome, as well as endoplasmic reticulum stress and disrupted homeostasis. These processes are described as contributing to initiation and progression of liver pathology through inflammatory and immune-mediated pathways.
The grounding supports exposure to viruses, alcohol, and drugs as factors associated with liver disease. It also suggests that changes in the gut microbiota and related host-microbe interactions may be associated with liver disease, but does not provide a more specific risk-factor list.
The supplied grounding does not provide a disease-specific standard treatment approach for liver diseases as a whole. It only indicates that the literature covers therapy and drug therapy at a broad level, without supporting a specific modality or drug class for the umbrella category.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Pathological processes of the LIVER.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.